Drug intelligence / Profile preview

CCT-987

Development stage: Preclinical
Lead developer: Canary Cure
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

CCT-987 is a preclinical siRNA-based therapeutic being developed by Canary Cure for the treatment of rare pediatric obesity, specifically Prader-Willi Syndrome (PWS) and hypothalamic obesity. Built on Canary Cure's dual RNA therapeutic platform, CCT-987 is designed to modulate gene expression pathways to reverse functional genetic disorders and increase muscle mass. The drug aims to address the underlying genetic and metabolic drivers of hyperphagia and obesity in these rare pediatric populations.

Beyond the preview

Go deeper on CCT-987.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCT-987.

Explore the full profile